Apnimed Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
65
- Stock Symbol
-
APMD
- Investments
-
2
- Share Price
-
$16.09
- (As of Friday Closing)
Apnimed General Information
Description
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Contact Information
Website
www.apnimed.comCorporate Office
- 39 John F. Kennedy Street
- 4th Floor
- Cambridge, MA 02138
- United States
Corporate Office
- 39 John F. Kennedy Street
- 4th Floor
- Cambridge, MA 02138
- United States
Apnimed Timeline
Apnimed Stock Performance
As of 20-Nov-2026, Apnimed’s stock price is $16.09. Its current market cap is $670M with 41.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.09 | $17.23 | $13.88 - $35.29 | $670M | 41.6M | 456K | $35.88 |
Apnimed Financials Summary
As of 31-Mar-2026, Apnimed has a trailing 12-month revenue of $120M.
|
In Thousands, USD |
TTM 31-Mar-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|---|
| Revenue | 120,000 | 120,000 | 38,467 | 8,012 |
| EBITDA | (2,317) | (114,211) | ||
| Net Income | (932) | (111,305) | ||
| Total Assets | 72,873 | 109,223 | ||
| Total Debt | 41,519 | 1,095 |
Apnimed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Apnimed Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Apnimed Patents
Apnimed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024379175-A1 | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent | Pending | 17-Nov-2023 | ||
| EP-4808533-A1 | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent | Pending | 17-Nov-2023 | ||
| WO-2025106773-A1 | Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent | Inactive | 17-Nov-2023 | ||
| WO-2024220343-A1 | Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea | Inactive | 18-Apr-2023 | ||
| AU-2023335927-A1 | Methods and compositions for treating sleep apnea | Pending | 02-Sep-2022 | A61K31/4725 |
Apnimed Signals
Apnimed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Apnimed Investments (2)
Apnimed’s most recent deal was a Corporate Asset Purchase with Desitin Arzneimittel (Global Rights to Patents Covering Sulthiame). The deal was made on 23-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Desitin Arzneimittel (Global Rights to Patents Covering Sulthiame) | 23-Apr-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Shionogi-Apnimed Sleep Science | 31-Oct-2023 | Joint Venture | Drug Discovery |
Apnimed FAQs
-
When was Apnimed founded?
Apnimed was founded in 2017.
-
Where is Apnimed headquartered?
Apnimed is headquartered in Cambridge, MA.
-
What is the size of Apnimed?
Apnimed has 65 total employees.
-
What industry is Apnimed in?
Apnimed’s primary industry is Drug Discovery.
-
Is Apnimed a private or public company?
Apnimed is a Public company.
-
What is Apnimed’s stock symbol?
The ticker symbol for Apnimed is APMD.
-
What is the current stock price of Apnimed?
As of 20-Nov-2026 the stock price of Apnimed is $16.09.
-
What is the current market cap of Apnimed?
The current market capitalization of Apnimed is $670M.
-
What is Apnimed’s current revenue?
The trailing twelve month revenue for Apnimed is $120M.
-
What is Apnimed’s annual earnings per share (EPS)?
Apnimed’s EPS for 12 months was $35.88.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process